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The metabolic activation of vitamin D is initiated by 25-hydroxylation of the side chain followed by a 1α-hydroxylation. 1α,25-Dihydroxyvitamin D 3 (calcitriol), the biologically most active form of vitamin D 3 , is known as a calcium-regulating hormone but is involved also in other processes such as modulation of the immune system and cell proliferation and differentiation. Currently, at least four enzymes capable of 25-hydroxylation of vitamin D 3 and/or vitamin D 2 have been described in humans, including the mitochondrial CYP27A1 and the microsomal CYP2R1, CYP2J2 and CYP3A4 (Prosser and Jones, 2004; Ohyama and Yamasali, 2004) . CYP3A4 is reported to prefer the non-physiological form vitamin D 2 over vitamin D 3 (Gupta et al., 2004) . Thus, several possible candidates as vitamin D 3 25-hydroxylase have been suggested but from a regulatory perspective, the physiological roles of these proposed 25-hydroxylases remain poorly defined. In this context, it is interesting that vitamin D 3 25-hydroxylation occurs also in certain extrahepatic tissues, e.g. the prostate. Regulation of human vitamin D 3 25-hydroxylation may be particularly important in extrahepatic tissues and might be a means of controlling cellular levels of 25-hydroxyvitamin D 3 and 1α,25-dihydroxyvitamin D 3 . This might influence cell function because these vitamin D 3 metabolites are reported to be active hormones in human prostate cells and to have antiproliferative properties (Tokar and Webber, 2005; Lou et al., 2004) .
In previous studies, both vitamin D metabolites and drugs affecting bone health have been shown to affect the promoter of the porcine vitamin D 25-hydroxylase, CYP2D25, in liver-derived HepG2 cells (Ellfolk et al, 2006; Hosseinpour et al., 2007) . In the present study, the expression and regulation of human 25-hydroxylating enzymes are examined in dermal fibroblasts and prostate cancer LNCaP cells. The effects on gene expression and endogenous 25-hydroxylase enzyme activity by 1α,25-dihydroxyvitamin D 3 and the drugs phenobarbital and efavirenz are examined. Phenobarbital is an antiepileptic drug, often used in combination with other drugs. Efavirenz is an antiretroviral drug, always used in This article has not been copyedited and formatted. The final version may differ from this version.
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This article has not been copyedited and formatted. The final version may differ from this version. Cell culture. Dermal fibroblast cells (BJ) were cultured in MEM supplemented with 10 % fetal bovine serum, 1 % non essential amino acids, 1 % antibiotic-antimycotic and 1% sodium pyruvate. LNCaP cells were cultivated in RPMI 1640 supplemented with 10% fetal bovine serum and 1% antibiotic-antimycotic. Both types of cells were grown in 5% CO 2 at 37°C .The cells were seeded the day before treatment and were kept in their growth medium overnight.
Treatment of cells.
Cells were treated with either calcitriol (0.1 nM), phenobarbital (1.5 mM) or efavirenz (2.5 µg/ml) for 24 h prior to extraction of total RNA or addition of 1α-hydroxyvitamin D 3 . The treatments were carried out in serum free media. 1α,25-Dihydroxyvitamin D 3 and efavirenz were dissolved in 99% ethanol. The vehicle, ethanol (99%) was used as control treatment.
This article has not been copyedited and formatted. The final version may differ from this version. (Nishimura et al., 2002) , and for the CYP2J2 reverse primer (Marden et al., 2003) . The CYP2R1 primers were those found in PrimerBank (Wang and Seed, 2003) . The forward primer is the forward primer of Primer Pair 1, with the Primer BankID 33591222a1 and the reverse primer is the reverse primer from PrimerPair 3 with the Primer BankID 33591222a3. The primers for CYP3A4 were those described previously (Hakkola et al., 1996) . The primers for CYP27A1 were as follows:
forward, 5´-AGT ACG GAA CGA CAT GGA GC-3´ , and reverse, 5´-GCA GAG TCT CCT TAA GCA CAG C-3´ (Garuti et al., 1996) . GAPDH was used as internal control. The PCR cycles were as follows: 95°C for 10 min, and then 35 cycles of denaturation (1 min at 94°C), annealing (1 min at 60°C) and extension (1 min at 72°C) followed by a final extension for 10 min at 72°C.
Quantitation of CYP2J2, CYP2R1 and CYP27A1 mRNA by real-time RT-PCR.
Quantitation of CYP2J2, CYP2R1 and CYP27A1 mRNA in fibroblasts and LNCaP cells was Targets and controls were amplified in triplicates as singleplex asssays. All expression data were normalized to the endogenous control. The relative mRNA expression levels were calculated according to the standard curve method as described by Applied
Biosystems. Standard curves were generated by serial five-fold dilutions of the cDNA of the positive control.
Analysis of vitamin D receptor, pregnane X receptor and constitutive androstane receptor expression. Analysis of endogenous VDR, PXR and CAR expression in fibroblasts
(BJ) and LNCaP cells was carried out by semi-quantitative RT-PCR. The primers used were those described for VDR (Pascussi et al., 2005) , for PXR (Noreault et al., 2005) and for CAR (Chang et al., 2003) . Human liver mRNA was used as positive control.
Statistical analysis. Statistical analysis was performed using one-way ANOVA. P values <0.05 were considered statistically significant.
This article has not been copyedited and formatted. The final version may differ from this version. Effects of phenobarbital on the mRNA levels of human vitamin D 25-hydroxylases. In a previous study, using the pig as model, we reported direct effects by phenobarbital on the expression of CYP27A1 and CYP2D25, two important 25-hydroxylases. In the current study, the effects of phenobarbital treatment on human vitamin D 3 25-hydroxylases were studied in prostate cancer LNCaP cells and dermal fibroblasts.
LNCaP cells were treated with phenobarbital (1.5 mM) in order to study its effects on the mRNA expression of the two vitamin D 25-hydroxylases CYP2J2 and CYP2R1. Phenobarbital significantly suppressed the expression of CYP2J2 by about 50 %, whereas CYP2R1 expression was unaffected in this cell line (Fig. 1A ). Fibroblasts were treated with phenobarbital in the same way to study its effects on the mRNA expression of the two vitamin D 25-hydroxylases CYP2R1 and CYP27A1. Phenobarbital significantly suppressed the expression of CYP2R1 by about 35 %, whereas CYP27A1 expression was unaffected (Fig. 1B) .
Effects of efavirenz on the mRNA levels of human vitamin D 25-hydroxylases. LNCaP cells were treated with the antiretroviral drug efavirenz to study its effects on the mRNA expression of CYP2J2 and CYP2R1. Efavirenz significantly suppressed the levels of CYP2J2 by 25% ( Fig. 2A ). Fibroblasts were treated with efavirenz in the same way to study its effect on the expression of CYP2R1 and CYP27A1. Efavirenz significantly suppressed CYP2R1 mRNA expression in fibroblasts by about 60%, whereas CYP27A1 did not respond to this treatment (Fig. 2B) . It may be concluded that efavirenz suppresses CYP2R1 mRNA expression in fibroblasts but not in LNCaP cells. This difference in regulation by efavirenz on CYP2R1 is correlated with expression of PXR in fibroblasts but not in LNCaP cells.
This article has not been copyedited and formatted. The final version may differ from this version. 1α,25-Dihydroxyvitamin D 3 significantly suppressed CYP2R1 by about 50%, whereas it had no clear effect on the levels of CYP2J2 (Fig. 3A) . Fibroblasts were treated with 1α,25-dihydroxyvitamin D 3 in the same way to study its effect on the expression of CYP2R1 and CYP27A1. 1α,25-Dihydroxyvitamin D 3 significantly suppressed the expression of CYP2R1
by about 50%, whereas CYP27A1 expression was only slightly suppressed by the vitamin D metabolite (Fig. 3B) . The results indicate that 1α,25-dihydroxyvitamin D 3 downregulates the expression of CYP2R1 in fibroblasts and LNCaP cells, both cell types expressing VDR.
Effects of efavirenz on the vitamin D 25-hydroxylase activity in fibroblasts.
On incubating cultured fibroblasts with 1α-hydroxyvitamin D 3 as substrate, 25-hydroxylation could be determined by the appearance of the product 1α,25-dihydroxyvitamin D 3 . The treatment concentration of efavirenz (2.5 µg/ml) is within the therapeutic window (1000-4000 µg/L) (Marzolini et al., 2001 ). The production of 1α,25-dihydroxyvitamin D 3 was suppressed about 30% by efavirenz (Fig. 4A) . The suppression by efavirenz was statistically significant.
Efavirenz was not used as treatment for experiments on enzyme activity in prostate cancer LNCaP cells because its effects on the mRNA levels of the two 25-hydroxylases present in LNCaP cells as described above were found to be marginal.
Effects of 1α,25-dihydroxyvitamin D 3 on the vitamin D 25-hydroxylase activity in
fibroblasts. The 25-hydroxylase activity in fibroblasts was determined by assay of the This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 4B) .
Metabolism of 1α-hydroxyvitamin D 3 in LNCaP cells
In This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
In previous studies, vitamin D metabolites and phenobarbital, a drug affecting bone health, have been found to suppress the promoter activity of the porcine vitamin D 25-hydroxylase, CYP2D25 (Ellfolk et al., 2006; Hosseinpour et al., 2007) . In this study, we report that phenobarbital and the antiretroviral drug efavirenz, as well as the active hormone 1α,25-dihydroxyvitamin D 3 (calcitriol) suppress the expression levels also of human 25-hydroxylating enzymes. In humans, several possible candidates for vitamin D 3 or vitamin D 2 25-hydroxylase have been suggested, including CYP27A1 (Theodoropoulos et al., 2002) , CYP2R1 (Cheng et al., 2003) , CYP2J2 (Aiba et al., 2006) , and CYP3A4 (Gupta et al., 2003) .
In recent years, the bioactivation of vitamin D 3 in extrahepatic cells has been subject to increased interest due to the regulating functions ascribed to 1α,25-dihydroxyvitamin D 3
(calcitriol) in cell proliferation and differentiation. In particular, the formation of the active vitamine D hormone has been studied in prostate cells and other cells in relation to cancer (Lou et al., 2004) . Whereas regulation of the 1α-hydroxylation step, catalyzed by CYP27B1, has been studied extensively, the regulation of the different 25-hydroxylating enzymes in the bioactivation of vitamin D 3 in various tissues is still unclear (Prosser and Jones, 2004) The data in the present study support our previous hypothesis that vitamin D 3 25-hydroxylation may be suppressed by phenobarbital (Hosseinpour et al., 2007) . A downregulation of 25-hydroxylation by phenobarbital may explain, at least in part, the increased risk of osteomalacia, bone loss and fractures in long-term phenobarbital therapy.
Osteomalacia and severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz have been described in a case report (Gyllensten et al., 2006) . This article has not been copyedited and formatted. The final version may differ from this version. Statistically significant difference (*P<0.05 and ***P<0.001). (n=3-6). Statistically significant difference (*P<0.05 and **P<0.01). The amount of product formed in the experiments shown in Fig. 4A was 61+10 ng and 36+6 ng, respectively. The difference in production rate between ethanol-treated (EtOH) and efavirenz-treated (efz) cells is statistically significant (*P<0.02). This article has not been copyedited and formatted. The final version may differ from this version. 
